Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|Metastatic Solid Tumors
Interventions: DRUG: BGJ398|DRUG: BYL719
Sponsor: Novartis Pharmaceuticals